Skip to main content
Premium Trial:

Request an Annual Quote

Judy Lieberman


Alnylam Pharmaceuticals has named Judy Lieberman, a senior investigator at the CBR Institute for Biomedical Research and a professor at Harvard Medical School, to its scientific advisory board.

The appointment comes a little more than a month after Alnylam licensed delivery technology developed by Lieberman from Harvard.

Lieberman holds a PhD in physics from Rockefeller University and an MD from the joint Harvard-Massachusetts Institute of Technology program in health, science, and technology.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.